La Nostra Storia
Abiogen Pharma’s continuity in research was triggered by the strong desire of Dr. Massimo Di Martino. Galileo Research inherits Abiogen Pharma’s desire to keep alive and in continuous efficiency the achievements gained in many years of study and application started in the nineteen-seventies.
Since its foundation, the Research Centre (now Galileo Research), worked on major studies in the field of ostoearticular metabolism, that resulted in the discovery of effective drugs for the treatment of bone pathologies: Bisphosphonates. This success culminated with the transfer of the worldwide rights of Alendronate to Merck Sharp & Dohme and of Clodronate to Boerhinger Mannheim, which then encouraged the Research Centre to look towards the fields of pharmacology where many needs are still to be met and where growing knowledge can create openings to new important achievements.
It is with this assumption that the research projects have been geared towards the CNS, oncology and degenerative diseases, for the synthesis of new molecules in both the fields of biotechnology and advanced therapies. Thus, developing technological backgrounds and innovative projects/products in cooperation with international partners, without abandoning those areas of research that have brought success and results in the past.
Tumours, the CNS and degenerative diseases are today the fields of study of Galileo Research, focusing on few and promising R&D projects.